These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. https://joanhawz542210.theideasblog.com/39634330/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide